Not yet recruitingInterventionalPhase 1Last updated Aug 14, 2026

Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants

A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of a Single Subcutaneous Administration of IBI3040 in Healthy Participants and Multiple Subcutaneous Administrations in Overweight or Obese Participants

Overview

ClinicalTrials.gov ID: NCT07765160
Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY
Brief Summary: Clinical trials of IBI3040 with single-dose administration in healthy participants and multiple-dose administration in overweight or obese participants.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Aug 30, 2026Estimated
Primary Completion Date: Nov 10, 2027Estimated
Completion Date: Dec 10, 2027Estimated

Study Record Dates

First Submitted: Aug 11, 2026
First Submitted that Met QC Criteria: Aug 11, 2026
First Posted: Aug 14, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 11, 2026
Last Update Posted: Aug 14, 2026Actual
Last Verified: Aug 2026

NCT07160400Recruiting

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

NCT07456839Active, not recruiting

A Mutiple-dose Study of IBI3033 in Healthy Participants

NCT07134127Completed

A Study of IBI3032 in Chinese Healthy Subjects

NCT07170319Active, not recruiting

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

NCT07311226Active, not recruiting

A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants

NCT04440345Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects